IMUGENE LIMITED — Director's Dealing 2013

Dec 23, 2013

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.	Amended 01/01/11	Amended 01/01/11
Name of Entity:		Imugene Limited (ASX:IMU)
ACN:		009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	6thNovember 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest	Indirect
Nature of indirect interest	Director related entities
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Date of change	20thDecember 2013
No. of securities held prior to change			Shares		Options
		Direct	-		-
		Indirect	-		-
		Total	-		-
Class
	Ordinary Shares (escrowed until				20 December
	2014)
Number acquired			Shares		Options
		Direct	-		-
		Indirect	68,296,875		-
		Total	68,296,875		-
Number disposed			Shares		Options
		Direct	-		-
		Indirect	-		-
		Total	-		-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote:If consideration is non-cash, provide details and estimatedvaluation	$0.016 per	$0.016 per	share
No. of securities held after change				Options---
			Shares	Options
		Direct	-	-
		Indirect	68,296,875	-
		Total	68,296,875	-
Nature of changeExample:on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back		Issue of shares as consideration for theacquisition of Biolife Science QLD Limitedasapprovedbyshareholderson20December 2013.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or N/A contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided? The CFO Solution

24 December 2013

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011